Magdent

Magdent aims to revolutionize the world of dental implants with its innovative pulsed electromagnetic field (PEMF) healing abutments. The company’s patented device works with standard implants to unlock powerful healing by activating and accelerating the body’s natural biological processes. Magdent’s breakthrough technology has been proven to reduce inflammation, making it an essential component in suppressing peri-implantitis, a condition that occurs in about 40% of implant procedures and can lead to implant failure. The company’s miniaturized electromagnetic devices (MEDs) stimulate bone formation and improve the quality of both hard and soft tissue, shortening recovery time by up to two-thirds and enabling oral health professionals to improve patient outcomes, especially for high-risk patients such as heavy smokers, for whom traditional implants may not be possible. The company's PEMF healing abutments are revolutionizing dental care, drastically reducing inflammation and accelerating bone formation, resulting in a remarkable threefold decrease in recovery time, particularly impactful for high-risk chronic patients, leading to substantial cost savings for insurance companies. Additionally, the device addresses peri-implantitis, the leading issue in dental implantology, by promoting bone growth and effectively treating patients. The company is raising an A Round (2nd Half, 2024) looking for strategic and VC investments.

Magdent has raised $6.7M in total funding across 6 rounds. The company is currently at the Seed stage. Key investors include Catapult Education, Ran Tuttnauer, Undisclosed Investor(s).

Magdent was founded in 2010 by Shlomo Barak (Founder, CEO & Chairman), Moshe Neuman (Founder).

Magdent operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Implants. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Magdent is based in Mesada Street 9, Bnei Brak, Israel, Center District.